Navigation Links
Depomed To Present At Piper Jaffray 2013 Healthcare Conference
Date:12/2/2013

NEWARK, Calif., Dec. 2, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Piper Jaffray 25th Annual Healthcare Conference at The New York Palace Hotel in New York City.

The presentation at the Piper conference is scheduled for 12:10 pm EST (9:10 am PST) on Tuesday, December 3, 2013.  The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com.  A recording of the webcast will be archived for 30 days on the company's website.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and other products and product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at www.depomed.com.

CONTACT: August J. Moretti  
Depomed, Inc. 650-462-5900
amoretti@depomed.com

 


'/>"/>
SOURCE Depomed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Depomed Reports Third Quarter 2013 Financial Results
2. Depomed To Report Third Quarter Fiscal Year 2013 Financial Results On Tuesday, November 5, 2013
3. Depomed Sells Type 2 Diabetes Royalties And Milestones To PDL BioPharma For $240.5 Million
4. PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed
5. Depomed Expands Geographic Scope of License Agreement with Merck for Extended Release Metformin Patents
6. Depomed Reports Second Quarter 2013 Financial Results
7. Depomed To Report Second Quarter Fiscal Year 2013 Financial Results On Wednesday, August 7, 2013
8. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
9. Depomed Announces Appointment of Louis J. Lavigne, Jr. to Board of Directors
10. Depomed to Present at Wells Fargo Securities 2013 Healthcare Conference
11. Depomed To Present At Jefferies 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based ... to treat Parkinson,s disease (PD), has enrolled the first patient ... randomized, controlled, multicenter study involving patients with PD and taking ... over a 9-to-12-month period. The first stage is open label ... Participating sites include Denver , ...
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
(Date:5/10/2017)... -- Radiology has become the number one diagnostic tool ... to the number one ranking as a result.  More ... as the most complete and reliable method for clinical ... pain an MRI may confirm a suspected herniated disc ... entirely different treatment protocols.  In these circumstances, patients need ...
Breaking Medicine Technology:
(Date:5/23/2017)... Rosa, California (PRWEB) , ... May 23, 2017 ... ... health management (PHM) technology and a 2017 Best in KLAS category winner, has ... advantageous market position to extend and enhance its technology platform and product offerings,” ...
(Date:5/23/2017)... Newport Beach, CA (PRWEB) , ... May 23, 2017 , ... ... Capital Partners was honored to serve earlier this month as a Guest Speaker and ... by the British Royal Family and Common Purpose. , Walter Schindler ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... By all ... underway in Sonoma County. While officials call for diligence, asking homeowners to scout for ... at potential health concerns. Along with the annoying buzz of mosquitos is the buzz ...
(Date:5/23/2017)... ... May 23, 2017 , ... MedTech ... in the modern ART laboratory, to provide hands-on training utilizing cutting-edge equipment at ... NextGen LifeLabs, a MedTech Group Purchasing vendor , will provide specialized equipment ...
(Date:5/23/2017)... ... ... New patients from Charleston, SC, are now welcome to receive a full mouth ... or without a referral. A full mouth reconstruction can transform the appearance of the ... SC. Those who suffer from gum disease, misaligned teeth or jaw pain can also ...
Breaking Medicine News(10 mins):